共 50 条
- [41] Heterogeneous impact of an early IFN beta treatment on disability progression in relapsing-remitting MS subgroups with different baseline clinical profiles MULTIPLE SCLEROSIS, 2007, 13 : S59 - S59
- [47] Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS Journal of Neurology, 2012, 259 : 898 - 905